303 related articles for article (PubMed ID: 24259695)
21. Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus.
Goldstein I; Jones LA; Belkoff LH; Karlin GS; Bowden CH; Peterson CA; Trask BA; Day WW
Mayo Clin Proc; 2012 Sep; 87(9):843-52. PubMed ID: 22857780
[TBL] [Abstract][Full Text] [Related]
22. The discovery of avanafil for the treatment of erectile dysfunction: a novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor.
Sakamoto T; Koga Y; Hikota M; Matsuki K; Murakami M; Kikkawa K; Fujishige K; Kotera J; Omori K; Morimoto H; Yamada K
Bioorg Med Chem Lett; 2014 Dec; 24(23):5460-5. PubMed ID: 25455484
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of udenafil in Turkish men with erectile dysfunction of psychogenic and organic aetiology: a randomized, double-blind, placebo-controlled study.
Ortaç M; Çayan S; Çalişkan MK; Yaman MÖ; Okutucu TM; Semerci MB; Altay AB; Balbay MD; Özcan MF; Kadioğlu A
Andrology; 2013 Jul; 1(4):549-55. PubMed ID: 23785019
[TBL] [Abstract][Full Text] [Related]
24. The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis.
Corona G; Rastrelli G; Burri A; Jannini EA; Maggi M
Expert Opin Drug Saf; 2016; 15(2):237-47. PubMed ID: 26646748
[TBL] [Abstract][Full Text] [Related]
25. Vardenafil treatment for erectile dysfunction.
Crowe SM; Streetman DS
Ann Pharmacother; 2004 Jan; 38(1):77-85. PubMed ID: 14742800
[TBL] [Abstract][Full Text] [Related]
26. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction.
Kotera J; Mochida H; Inoue H; Noto T; Fujishige K; Sasaki T; Kobayashi T; Kojima K; Yee S; Yamada Y; Kikkawa K; Omori K
J Urol; 2012 Aug; 188(2):668-74. PubMed ID: 22704456
[TBL] [Abstract][Full Text] [Related]
27. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
28. Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation.
Scaglione F; Donde S; Hassan TA; Jannini EA
Clin Ther; 2017 Feb; 39(2):370-377. PubMed ID: 28139291
[TBL] [Abstract][Full Text] [Related]
29. Avanafil for treatment of erectile dysfunction: review of its potential.
Burke RM; Evans JD
Vasc Health Risk Manag; 2012; 8():517-23. PubMed ID: 22973106
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of udenafil for erectile dysfunction: a meta-analysis of randomized controlled trials.
Ding H; Du W; Wang H; Zhang L; Wang Z; Du C; Tao Y
Urology; 2012 Jul; 80(1):134-9. PubMed ID: 22497982
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of daily avanafil efficacy in improving the endothelial function in Egyptian males with erectile dysfunction.
Elkamshoushi AM; Badae NM; Kabary MG; Omar SI
Andrologia; 2021 Feb; 53(1):e13833. PubMed ID: 33112433
[TBL] [Abstract][Full Text] [Related]
32. An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.
Bruzziches R; Francomano D; Gareri P; Lenzi A; Aversa A
Expert Opin Pharmacother; 2013 Jul; 14(10):1333-44. PubMed ID: 23675780
[TBL] [Abstract][Full Text] [Related]
33. A phase II, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction.
Hellstrom WJ; Freier MT; Serefoglu EC; Lewis RW; DiDonato K; Peterson CA
BJU Int; 2013 Jan; 111(1):137-47. PubMed ID: 22788525
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial.
Zhao C; Kim SW; Yang DY; Kim JJ; Park NC; Lee SW; Paick JS; Ahn TY; Min KS; Park K; Park JK
Eur Urol; 2011 Aug; 60(2):380-7. PubMed ID: 21458153
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: A literature review].
Bacconi L; Gressier F
Encephale; 2017 Feb; 43(1):55-61. PubMed ID: 27658991
[TBL] [Abstract][Full Text] [Related]
36. The efficacy and safety of on-demand Elonza; a generic product of sildenafil in Thai men with erectile dysfunction.
Wijitsettakul U; Pempongkosol S
J Med Assoc Thai; 2013 Jun; 96(6):683-8. PubMed ID: 23951825
[TBL] [Abstract][Full Text] [Related]
37. [Sex, erectile dysfunction, and the heart: a growing problem].
Görge G; Flüchter S; Kirstein M; Kunz T
Herz; 2003 Jun; 28(4):284-90. PubMed ID: 12825143
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of vardenafil in patients with erectile dysfunction: result of a bridging study in Japan.
Nagao K; Ishii N; Kamidono S; Osada T;
Int J Urol; 2004 Jul; 11(7):515-24. PubMed ID: 15242361
[TBL] [Abstract][Full Text] [Related]
39. Avanafil for the Treatment of men With Erectile Dysfunction: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Li J; Peng L; Cao D; He L; Li Y; Wei Q
Am J Mens Health; 2019; 13(5):1557988319880764. PubMed ID: 31672076
[TBL] [Abstract][Full Text] [Related]
40. Adverse reactions of PDE5 inhibitors: An analysis of the World Health Organization pharmacovigilance database.
Lui JL; Shaw NM; Abbasi B; Hakam N; Breyer BN
Andrology; 2023 Oct; 11(7):1408-1417. PubMed ID: 36905319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
